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The innate immune system plays a dualistic role in the evolution of ischemic brain
damage and has also been implicated in ischemic tolerance produced by different
conditioning stimuli. Early after ischemia, perivascular astrocytes release cytokines and
activate metalloproteases (MMPs) that contribute to blood–brain barrier (BBB) disruption
and vasogenic oedema; whereas at later stages, they provide extracellular glutamate
uptake, BBB regeneration and neurotrophic factors release. Similarly, early activation
of microglia contributes to ischemic brain injury via the production of inflammatory
cytokines, including tumor necrosis factor (TNF) and interleukin (IL)-1, reactive oxygen
and nitrogen species and proteases. Nevertheless, microglia also contributes to the
resolution of inflammation, by releasing IL-10 and tumor growth factor (TGF)-β, and to the
late reparative processes by phagocytic activity and growth factors production. Indeed,
after ischemia, microglia/macrophages differentiate toward several phenotypes: the M1
pro-inflammatory phenotype is classically activated via toll-like receptors or interferon-γ,
whereas M2 phenotypes are alternatively activated by regulatory mediators, such as ILs
4, 10, 13, or TGF-β. Thus, immune cells exert a dualistic role on the evolution of ischemic
brain damage, since the classic phenotypes promote injury, whereas alternatively
activated M2 macrophages or N2 neutrophils prompt tissue remodeling and repair.
Moreover, a subdued activation of the immune system has been involved in ischemic
tolerance, since different preconditioning stimuli act via modulation of inflammatory
mediators, including toll-like receptors and cytokine signaling pathways. This further
underscores that the immuno-modulatory approach for the treatment of ischemic stroke
should be aimed at blocking the detrimental effects, while promoting the beneficial
responses of the immune reaction.
Keywords: cytokines, immune system, ischemic stroke, ischemic tolerance, macrophages, neutrophils,
preconditioning
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Introduction
As highlighted by recent expression profiling studies, the
majority of the genes acutely modulated in the blood of stroke
patients are implicated in the regulation of the innate immune
system (Tang et al., 2006; Barr et al., 2010; Oh et al., 2012;
Brooks et al., 2014). Moreover, serum levels of markers of acute
inflammation correlate with the severity of brain damage and
neurological deficit (Fassbender et al., 1994; Smith et al., 2004;
Basic Kes et al., 2008; Whiteley et al., 2009; Chang et al., 2010).
Indeed, the innate immune system plays a pivotal role in
the evolution of ischemic cerebral injury, as soluble mediators
(i.e., cytokines and chemokines) and specialized cells, activated
in the brain or recruited from the periphery, actively participate
to the detrimental processes implicated in tissue damage, as well
as to the repair and regeneration phases (Kamel and Iadecola,
2012; Amantea et al., 2014a). The dualistic role exerted by several
mediators of the immune reaction may explain why most anti-
inflammatory approaches, conceived disregarding the potential
beneficial function of the target, have failed to reach the clinical
setting.
In addition, a subdued activation of the immune system
has been involved in ischemic tolerance, since different
preconditioning stimuli act by reprogramming the immune
response, through the modulation of inflammatory mediators,
including toll-like receptors (TLRs) and cytokine signaling
pathways (Garcia-Bonilla et al., 2014a). This further underscores
that promoting the endogenous neuroprotective reactions of the
innate immune system represents an attractive opportunity to
develop novel effective stroke therapeutics.
This review has been conceived to describe the role played
by the diverse mediators of the innate immune system in
ischemic brain damage, also highlighting their beneficial role
with the ambition to stimulate more extensive research aimed at
selectively targeting these processes.
Cellular Mediators of the Immune
Response
Resident Immune Cells
All the cellular components of the neurovascular unit participate
to the inflammatory reaction involved in ischemic stroke
injury (Figure 1). On the intravascular side, platelets and
the complement system are rapidly activated after vessel
occlusion, thus providing the first trigger for the inflammatory
response (Atkinson et al., 2006; Nieswandt et al., 2011).
Elevated endothelial expression of the adhesion molecules
P-selectin and intercellular adhesion molecule (ICAM)-1
promotes polymorphonuclear leukocytes (PMN) recruitment
that exacerbates microvessel obstruction, also due to the reduced
bioavailability of nitric oxide (NO) (Granger et al., 1989; Mori
et al., 1992; Wong and Crack, 2008). Recently, Sreeramkumar
et al. (2014) have demonstrated that the interaction between
PMN and platelets within the microvasculature of infarcted
brains is inhibited by blocking P-selectin glycoprotein ligand-1
(PSGL-1), and this correlates with a significant decrease in
the infarct volume after permanent occlusion of the middle
cerebral artery. Moreover, the ischemia-induced release of
pro-inflammatory cytokines [e.g., interleukin (IL)-1 and tumor
necrosis factor (TNF)] further promotes adhesion molecules
expression and, together with the activation of proteases [i.e.,
matrix metalloproteases (MMPs)], prompts blood-brain barrier
(BBB) breakdown leading to leukocytes extravasation in the
injured brain (Ishikawa et al., 2004; Amantea et al., 2007; Yemisci
et al., 2009; Yilmaz and Granger, 2010).
Astrocytes are the most abundant glial cells of the human
brain and form part of the BBB. Ultrastructural studies have
shown that pericapillary astrocyte end-feet are the first cellular
elements to swell during cerebral ischemia (Dodson et al.,
1977). Cytokines and reactive oxygen species (ROS), released
by neurons and glial cells few minutes after the ischemic
insult, alter molecular expression patterns in astrocytes and
induce cellular hypertrophy, proliferation and scar formation
(Sofroniew, 2009). Moreover, stimulation of P2Y(1) receptors by
adenosine 5′-triphosphate (ATP), released or leaked from injured
cells, prompts production of pro-inflammatory cytokines and
chemokines by astrocytes via activation of a phosphorylated-
p65 subunit (RelA)-mediated NF-κB pathway (Kuboyama et al.,
2011). IL-1β and MMPs produced by perivascular astrocytes
participate to BBB disruption and vasogenic edema (Rosenberg
et al., 1998; del Zoppo and Hallenbeck, 2000; Amantea et al.,
2010). Nevertheless, astrocytes exposed to an ischemic insult
may also participate to neuroprotective and reparative responses
(Table 1) by extracellular glutamate uptake (Stanimirovic et al.,
1997; Rossi et al., 2007), BBB rebuilding (Kinoshita et al.,
1990; del Zoppo, 2009) and neurotrophic factors release (Shen
et al., 2010; Barreto et al., 2011). Accordingly, impairment of
astrocyte function amplifies ischemic neuronal death (Nakase
et al., 2003; Ouyang et al., 2007) and ablation of their reactivity
and proliferation delays neurovascular remodeling and disrupts
scar formation, negatively affecting functional recovery after
focal cerebral ischemia in rodents (Nawashiro et al., 2000; Li
et al., 2008; Hayakawa et al., 2010). Alternatively, proliferation
of astrocytes induced by environmental enrichment or by
pharmacological induction of signal transducer and activator
of transcription factor (STAT)-3 phosphorylation ameliorates
histological and functional outcomes in stroke models (Keiner
et al., 2008; Amantea et al., 2011). Thus, reactive astrogliosis
may exert a dualistic role on the propagation of ischemic brain
damage, depending on the polarization of astrocytes toward
specific phenotypes (Zamanian et al., 2012; Rusnakova et al.,
2013) and on their interaction with surrounding neurons and
microglia (Bezzi et al., 2001; Kang et al., 2012).
After an ischemic insult, microglia, the resident immune
cells of the central nervous system, is rapidly activated by ATP
released by damaged neurons and other glial cells, acting on P2X7
receptors to prompt production and release of pro-inflammatory
mediators (Melani et al., 2006; Dénes et al., 2007). Stimulation
of microglia also relies on TLR4 stimulation, fractalkine
receptor (CX3CR1) modulation and/or reduced CD200 receptor
stimulation evoked by ischemia-induced disturbance of neuron-
microglia cross-talk (Lehnardt et al., 2003; Dénes et al., 2008;
Dentesano et al., 2012).Moreover, the increased release of specific
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FIGURE 1 | Schematic drawing summarizing the major cellular and soluble mediators of the immune response elicited by an ischemic insult.
neurotransmitters, such as glutamate and γ-aminobutyric acid,
may elicit an inflammatory or a neuroprotective phenotype in
microglia by signaling through Nox (Pocock and Kettenmann,
2007; Mead et al., 2012).
Microglial activation is accompanied by a substantial
morphological transformation characterized in the early stages
by retraction of cellular processes and enlargement of cell bodies,
to ultimately acquire an amoeboid macrophage-like phenotype
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TABLE 1 | Dualistic effects of innate immune cells activated after ischemic brain injury.
Cell type Detrimental effects Beneficial effects
Astrocytes Production of inflammatory mediators (e.g., TNF-α, IL-1 and
MMPs).
Edema formation, inhibition of axon regeneration and BBB
disruption.
Extracellular glutamate uptake, synthesis and release of neurotrophic
factors.
Glial scar formation, BBB rebuilding and neurovascular remodeling.
Microglia/macrophages M-1 phenotype: production of pro-inflammatory cytokines,
including TNF and IL-1, reactive oxygen and nitrogen species and
proteases, such as MMPs.
M-2 phenotype: resolution of inflammation (IL-10 and TGF-β release,
production of arginase and phagocytic activity).
Late reparative processes by producing growth factors (IGF-1,
brain-derived neurotrophic factor and glial cell line-derived neurotrophic
factor).
Neutrophils Microvessel obstruction, ROS production and release of MMPs
that contribute to BBB damage and exacerbate inflammation.
N2 phenotype: promote resolution of inflammation
Dendritic cells Up-regulation of MHC-II and co-stimulatory molecules that prompt
activation of lymphocytes.
(Davis et al., 1994; Zhang et al., 1997; Schilling et al., 2003; Jung
and Schwartz, 2012). As reported both in ischemia animal models
(Zhang et al., 1997; Stoll et al., 1998; Dénes et al., 2007) and
in stroke patients (Gerhard et al., 2005; Price et al., 2006), the
reactivity and proliferation of microglia reach a peak few days
after the insult and may persist for several weeks.
Reactive microglia may enhance inflammation and ischemic
tissue injury via increased production and release of cytokines,
such as IL-1 and TNF (Barone et al., 1997; Rothwell et al., 1997;
Lambertsen et al., 2005; Amantea et al., 2010), reactive oxygen
and nitrogen species (Green et al., 2001) and proteases (del
Zoppo et al., 2007). These detrimental effects are underscored
by the evidence that pharmacological- or microRNA-induced
suppression of microglial activity limits ischemic cerebral injury
(Hailer, 2008; Fagan et al., 2011; Zhang et al., 2012). However,
other studies have demonstrated beneficial effects exerted by
microglia in experimental stroke settings (Kitamura et al.,
2004; Imai et al., 2007; Lalancette-Hébert et al., 2007). Indeed,
by producing IL-10, transforming growth factor (TGF)-β and
insulin-like growth factor (IGF)-1, microglia promotes resolution
of the inflammatory reaction and reparative mechanisms
involved in late tissue recovery (O’Donnell et al., 2002;
Lalancette-Hébert et al., 2007; Neumann et al., 2008; Ransohoff
and Cardona, 2010).
The reason for these apparently discrepant results can be
found in the aptitude of microglia/macrophages to differentiate
toward diverse phenotypes, depending on the dynamic evolution
of the ischemic damage (Clausen et al., 2008; Perego et al.,
2011). Indeed, the classic pro-inflammatory M1 phenotype is
activated by interferon (INF)-γ or through TLRs modulation,
whereas the alternatively activated M2 phenotype is induced by
regulatory factors, including interleukins 4, 10, 13, or TGF-β
(Italiani and Boraschi, 2014) (Table 1). Early after an ischemic
insult, local microglia assumes the M2 “beneficial” phenotype, to
then develop into a pro-inflammatory M1 phenotype prompted
by the ischemic neurons (Hu et al., 2012). Thus, in addition
to the classical approach aimed at suppressing detrimental
M1 functions (i.e., production of TNF-α, IL-1β, monocyte
chemoattractant protein (MCP)-1, macrophage inflammatory
protein (MIP)-1α, and IL-6), preservation of the alternatively
activated M2 phenotype may represent an innovative strategy
for stroke neuroprotection, as demonstrated in mice lacking the
class-A scavenger receptor (Xu et al., 2012) or the myeloid-
specific mineralcorticoid receptor (Frieler et al., 2011). Given
the similarities between local microglia and macrophages, as
well as the ability of microglia to develop active phenotypes
indistinguishable from circulating macrophages, further insights
into their polarization will be given in the following section.
Blood-Borne Cells
Genomic profile studies indicate a critical role of innate
immunity in regulating stroke response and recovery. The genes
identified in these profiles are involved in immune signaling
at different levels, including the cerebral microenvironment,
the vasculature and, most notably, the peripheral circulation
(Brooks et al., 2014). In the first analysis performed in stroke
patients, Moore et al. (2005) detected the expression of genes
associated with the regulation of the cerebral microenvironment
in peripheral blood mononuclear cells (PMBCs), thus supporting
the important finding that peripheral blood is reflective of
changes in the brain.
Interestingly, the majority of the genes identified in all the
stroke-specific profiles published to date are related to the
immune system (Moore et al., 2005; Tang et al., 2006; Barr et al.,
2010; Oh et al., 2012). Among these studies, Brooks et al. (2014)
recently identified a panel of overlapping genes, significantly
expressed within 3 h from stroke onset, including arginase1
(ARG1), carbonic anhydrase 4 (CA4), lymphocyte antigen 96
(LY96), matrix metalloproteinase 9 (MMP9), and S100 calcium
binding protein A12 (S100A12). Specifically, four of these genes
(ARG1, LY96, MMP9, S100A12) are implicated in the innate
immune response, the fifth (CA4) being highly expressed in the
BBB (Brooks et al., 2014).
These findings strongly support the theory that the immune
response to the ischemic insult engages specialized circulating
cells, such as neutrophils, macrophages, dendritic cells and T
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lymphocytes, that are recruited and migrate to the brain, upon
activation triggered by soluble factors released by injured and
dying cells (Price et al., 2004; Buck et al., 2008; Felger et al.,
2010; Yilmaz and Granger, 2010; Kamel and Iadecola, 2012).
Infiltrating leukocytes affect the evolution of tissue damage by
releasing a series of mediators including purines, ROS and danger
associated molecular patterns (DAMPs), such as high mobility
group box (HMGB)-1 protein, heat shock protein 60, β-amyloid,
DNA or RNA immune complexes (Amantea et al., 2014a).
Interestingly, the majority of the genes acutely regulated
in the blood of stroke patients are expressed in neutrophils
and, to a lesser extent, in macrophages (Tang et al., 2006).
Accordingly, these are the first cells to infiltrate the ischemic
brain, reaching a peak within 24–72 h after the insult (Clark
et al., 1994; Garcia et al., 1994; Gelderblom et al., 2009). In
patients, higher peripheral leukocyte and neutrophil counts, but
not lymphocyte counts, are associated with larger infarct volumes
(Buck et al., 2008), and brain accumulation of neutrophils
correlates with poor neurological outcome and brain damage
severity both in humans (Akopov et al., 1996) and in rodents
(Matsuo et al., 1994a,b; Connolly et al., 1996; Atochin et al., 2000).
In fact, neutrophils prompt microvessel obstruction/thrombosis
(del Zoppo et al., 1991; Ritter et al., 2005), production of
ROS and release of MMPs (Justicia et al., 2003; Gidday et al.,
2005; Bao Dang et al., 2013); thus, their modulation may
represent a useful strategy to ameliorate stroke outcome. This
may be achieved by pharmacological approaches, as well as
by remote ischemic preconditioning, as documented by the
evidence that forearm transient ischemia reduces neutrophil
function, including adhesion, exocytosis, phagocytosis and
cytokine secretion (Shimizu et al., 2010).
Interestingly, recent findings have highlighted the ability
of neutrophils to polarize toward beneficial N2 phenotypes.
In the setting of stroke, neutrophil reprogramming can be
induced by activation of the nuclear peroxisome proliferator-
activated receptor (PPAR)-γ (Cuartero et al., 2013). Thus, despite
promoting early neutrophil infiltration to the ischemic core,
the PPAR-γ agonist rosiglitazone provides neuroprotection and
resolution of inflammation after experimental stroke induced by
permanent MCAo by promoting N2-polarization and increased
neutrophil clearance (Cuartero et al., 2013).
Likewise neutrophils, hematogenous macrophages infiltrating
the ischemic brain (Schilling et al., 2003; Jander et al., 2007),
exert a dualistic role on the evolution of tissue damage (Frieler
et al., 2011; Hu et al., 2012; Xu et al., 2012). In fact, they
possess the ability to switch between the classically activated
M1 phenotype and alternatively activated M2 phenotypes
(Ballesteros et al., 2014a) (Table 1). The M1 cells initiate and
sustain inflammation by releasing neurotoxic factors and ROS
that underlie macrophage/microglia-mediated neurotoxicity
after stroke; whereas,M2-polarized cells are involved in beneficial
responses by clearing debris and by promoting angiogenesis,
tissue remodeling and repair (Gliem et al., 2012; Shechter and
Schwartz, 2013). Up-regulation of M2 markers observed in the
ischemic brain (Frieler et al., 2011; Perego et al., 2011; Hu
et al., 2012; Zarruk et al., 2012; Ballesteros et al., 2014a) is due
to an increased cerebral infiltration of alternatively activated
blood-borne monocytes (Perego et al., 2011), as well as to
the ability of local microglia/macrophages to assume an M2
phenotype (Hu et al., 2012). Indeed, local microglia and newly
recruited macrophages assume the M2 phenotype at early stages
of ischemic stroke but, upon priming by ischemic neurons,
gradually transform into the M1 phenotype (Hu et al., 2012).
The exact mechanisms that control macrophage polarization
in the setting of stroke have not been fully elucidated, as
well as it is not clear whether the acquisition of a specific
phenotype involves recruitment of circulating precursors or
in situ cell re-instruction. Endogenous production of the M2-
polarizing cytokine IL-4, triggered by MCAo in mice, has
been shown to promote Th2 polarization and, thus, beneficial
effects on stroke outcome (Xiong et al., 2011). Further studies
have shown that a subpopulation of bone marrow-derived
monocytes/macrophages, recruited via CCR2 and acting through
TGF-β1, maintains the integrity of the neurovascular unit in
murine stroke models (Gliem et al., 2012).
To date, only few studies have assessed the therapeutic benefits
of reducing the M1/M2 ratio in stroke setting. Frieler et al.
(2011) showed that deficiency of the mineralcorticoid receptor
(MR) decreases the expression of M1 markers, while preserving
the ischemia-induced expression of M2 markers. The resulting
elevation of M2 polarized myeloid cells in the ischemic brain was
correlated with a better stroke outcome in MR−/− mice (Frieler
et al., 2011). Similarly, deficiency of the fractalkine receptor
CX3CR1 has been associated with a protective inflammatory
milieu, characterized by the promotion of M2 polarization
markers (Fumagalli et al., 2013). PPAR-γ-mediated CD36 up-
regulation has been involved in the modulation of microglia
phenotype, promoting phagocytosis of apoptotic neutrophils,
and thus contributing to the resolution of inflammation after
stroke (Ballesteros et al., 2014b). By contrast, elevation of M1/M2
ratio promoted by the class A scavenger receptor expressed in
microglia/macrophages has been associated with exacerbation
of ischemic brain injury (Xu et al., 2012). At variance with the
latter, the selective cannabionoid receptor 2 agonist, JWH-133,
provides neuroprotection in the acute phase of ischemic stroke by
reducing microglia activation, without affecting M2 polarization
(Zarruk et al., 2012).
Although preclinical findings strongly suggest the therapeutic
usefulness of M2-polarizing agents, the exact mechanisms
modulating M1/M2 ratio need further investigation and their
relevance for stroke outcome in human stroke has to be validated.
At later stages after the ischemic insult, a significant elevation
of dendritic cells occurs in the injured brain hemisphere, reaching
a peak 72 h after the insult (Kostulas et al., 2002; Reichmann et al.,
2002; Gelderblom et al., 2009). Both peripheral and brain resident
dendritic cells are pivotally involved in bridging innate and
adaptive immunity by up-regulating major histocompatibility
complex (MHC)-II and co-stimulatory molecules that contribute
to the activation of lymphocytes (Gelderblom et al., 2009;
Felger et al., 2010). Moreover, resident dendritic cells participate
in orchestrating the early local immune response and in the
late recruitment of lymphocytes (Felger et al., 2010) following
activation by INF-γ (Gottfried-Blackmore et al., 2009). Brain
infiltration of T lymphocytes occurs relatively late (i.e., 3–7
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days) after ischemia (Jander et al., 1995; Schwab et al., 2001;
Gelderblom et al., 2009); nevertheless, these cells contribute to
the progression of brain damage (Yilmaz et al., 2006; Hurn
et al., 2007; Jin et al., 2010), exerting distinct effects depending
on the specific cell subset recruited (Amantea et al., 2014a).
Recent evidence demonstrates that the functional sphingosine-
1-phosphate receptor agonist FTY720 (fingolimod), minimizes
brain damage and functional deficits in experimental stroke
(Shichita et al., 2009; Hasegawa et al., 2010; Wei et al., 2011).
Interestingly, the putative elevation of the incidence of bacterial
pneumonia caused by the inhibition of the adaptive immunity
by fingolimod does not seem to be actually relevant for the
neuroprotective effects of the drug (Pfeilschifter et al., 2011).
Thus, the ischemic insult is associated to a relevant activation
of the innate immune system, involving both local and blood-
borne specialized cells that, upon recruitment, modulate the
cerebral inflammatory response to stroke and set the stage for the
activation of adaptive immunity (Figure 1).
Molecular Mediators of the Immune
Response
Receptors
As stated above, activation of P2X7 receptors on microglia
prompts the processing and release of pro-inflammatory
cytokines (Brough et al., 2002; Melani et al., 2006). Moreover,
overactivation of P2X7 receptors is involved in excitotoxic
neuronal death (Arbeloa et al., 2012) and participates to
ischemia-induced damage to olygodendrocytes and myelin
(Domercq et al., 2010).
Activation of TLRs by HMGB1, peroxiredoxin (Prx) proteins
and other DAMPS, plays an important role in ischemic brain
injury (Fossati and Chiarugi, 2007; Shichita et al., 2012a,b;
Pradillo et al., 2014). In particular, TLR2 and TLR4 crucially
contribute to the induction of the inflammatory response and
to the evolution of brain damage, as documented by the
evidence that TLR2- or TLR4-deficiency is associated to reduced
ischemic brain damage and to suppression of ischemia-induced
expression and release of inflammatory cytokines (Tang et al.,
2007; Hyakkoku et al., 2010). Indeed, TLR4 deficient mice display
significant suppression of IκB phosphorylation, NFκB activity,
pro-inflammatory mediators, including TNF-α and IL-6 (Cao
et al., 2007; Hyakkoku et al., 2010) and the enzymes inducible
nitric oxide synthase (NOS) and cyclooxygenase (COX)-2 (Caso
et al., 2007, 2008).
The relevance of TLR2 and TLR4 has also been demonstrated
in ischemic stroke patients, since up-regulation of these receptors
is associated with greater inflammatory responses and with
poor functional outcome (Brea et al., 2011). The stimulation of
macrophages and T cells by TLRs-associated pathways induces
strong inflammatory responses (Shichita et al., 2012a). Following
cerebral ischemia, the activation of TLR4 by HMGB-1 induces
MMP-9 up-regulation in neurons and astrocytes (Qiu et al., 2010)
and promotes detrimental effects by macrophages infiltrating the
injured brain (Yang et al., 2011). In fact, cerebral microinjection
of HMGB-1 increases the transcript levels of pro-inflammatory
mediators and sensitizes the tissue to ischemic injury (Faraco
et al., 2007). In addition, deficiency of TLR4 in young animals
subjected to focal cerebral ischemia, promotes subventricular
zone cell proliferation, increasing the number of the transit-
amplifying cells (type C cells; prominin-1+/EGFR+/nestin-
cells) at 24 and 48 h, of proliferating immature (BrdU+) cells at
7d and of neuroblast cells (type A cells; doublecortin+ cells) at
14d (Moraga et al., 2014). Despite a negative effect on SVZ cell
proliferation, TLR4 plays an important role in stroke-induced
neurogenesis by promoting neuroblasts migration and increasing
the number of new cortical neurons after stroke (Moraga et al.,
2014).
Although the exact mechanisms by which TLRs modulate the
evolution of ischemic brain injury have not been fully elucidated,
pharmacological inhibition of TLR2 and TLR4 and/or blockade
of some of their endogenous ligands (i.e., cellular fibronectin or
heat shock protein 60), represent promising therapeutic options,
effective in reducing the inflammatory response to stroke injury
(Brea et al., 2011).
Paradoxically, by reprogramming TLRs signaling,
stimulation of TLRs before ischemia leads to suppression
of pro-inflammatory responses and to enhanced expression
of numerous anti-inflammatory mediators that collectively
contribute to neuroprotection (Pradillo et al., 2009; Vartanian
et al., 2011). Activation of TLR4 by low doses of LPS reduces
synthesis and release of some pro-inflammatory cytokines,
and inhibits microglial activation and neutrophil infiltration,
thus reducing ischemic brain injury (Rosenzweig et al., 2004;
Pradillo et al., 2009). Tolerance to brain ischemia induced by
low doses of the major TLR4 ligand, LPS, administered 1–3 days
before the insult, has been demonstrated in several experimental
stroke models (Tasaki et al., 1997; Hickey et al., 2007; Yu
et al., 2010). Recent work has also demonstrated that ischemic
preconditioning reduces brain damage from permanent middle
cerebral artery occlusion in mice by increasing expression
of TLR3 in cortical astrocytes (Pan et al., 2014). Therefore,
induction of ischemic tolerance by subdued TLRs activation
represents an interesting opportunity to exploit these receptors
for stroke therapy.
The receptor for advanced glycation end products (RAGE)
is a member of the immunoglobulin family of cell surface
receptors and has been implicated in the development and
progression of stroke. The full-length, membrane-bound RAGE
isoform (fl-RAGE) is mainly expressed in neurons and in
microglia/macrophages. Up-regulation of this receptor has been
documented after both permanent and transient focal cerebral
ischemia in rodents (Qiu et al., 2008; Zhai et al., 2008;
Hassid et al., 2009) and in the ischemic hemisphere of stroke
patients (Hassid et al., 2009). More specifically, ischemia-induced
modifications of the expression of RAGE and its isoforms in the
brain strongly depends on the intensity and on the propagation
of the insult; showing a distinct modulation in the core and
penumbra regions (Greco et al., 2012, 2014). By activating fl-
RAGE on microglia/macrophages, HMGB-1 protein released
from dying neurons, contributes to the development of ischemic
brain damage (Muhammad et al., 2008; Qiu et al., 2008).
Conversely, blockade of fl-RAGE signaling promotes cell survival
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and reduces stroke infarct volume in animal models (Kim et al.,
2006; Liu et al., 2007; Muhammad et al., 2008).
A reduced plasma level of soluble RAGE isoforms (sRAGE)
has been reported in rats subjected to either transient or
permanent focal brain ischemia (Greco et al., 2012, 2014). This
is of significance since sRAGE, generated either by alternative
splicing or by proteolysis of the full-length form, effectively bind
AGEs, thereby competing with the cell surface fl-RAGE, thus
providing a “decoy” function thatmay counteract the detrimental
effects of receptor signaling in neurons (Koyama et al., 2007;
Muhammad et al., 2008; Tang et al., 2013). Interestingly, the
reduction of sRAGE levels induced by transient MCAo in rats,
is minimized by pre-treatment with a neuroprotective dose of
the poly(ADP-ribose) polymerase (PARP) inhibitor PJ34 (Greco
et al., 2014), suggesting that sRAGE may represent a useful
biomarker of stroke severity and of effective neuroprotective
treatment. In patients, some studies have reported an association
between circulating sRAGE levels and brain infarct volume,
stroke severity (Park et al., 2004; Yokota et al., 2009) and
inflammatory status (Cui et al., 2013), others have suggested that
sRAGE levels at onset may predict cognitive impairment after
cerebral ischemia (Qian et al., 2012).
Inflammatory Cytokines
The inflammatory response to ischemic brain injury is
orchestrated by a variety of cytokines released by resident brain
cells, such as neurons and glia, and by blood-borne immune cells.
TNF, IL-1 and IL-6 strongly affect the development of ischemic
brain damage in animal models, and their levels are increased
in the blood and in the cerebrospinal fluid of stroke patients
(Lambertsen et al., 2012), thus attracting considerable interest
as putative markers of stroke severity and neurologic outcome
(Emsley et al., 2007; Jickling and Sharp, 2011). By contrast, other
cytokines, including IL-10 and TGF-β exert immunoregulatory
and anti-inflammatory effects, thus promoting reparative
processes. In addition, mild systemic inflammation induced by
remote preconditioning is neuroprotective in stroke models
(Petcu et al., 2008) and several soluble mediators of the innate
immune system have been involved in ischemic tolerance
produced by diverse preconditioning stimuli (Garcia-Bonilla
et al., 2014a).
A significant and rapid up-regulation of TNF-α occurs
following focal cerebral ischemia both in animal models and in
stroke patients. In fact, expression of this cytokine is elevated
in neurons during the first hours after the insult; whereas, at
later stages, it is increased in microglia/macrophages and in
blood-borne immune cells (Gregersen et al., 2000; Dziewulska
and Mossakowski, 2003). Accordingly, recent flow cytometry
experiments have demonstrated that the major source of this
cytokine in the stroke-lesioned mouse brain is microglia and
macrophages (Clausen et al., 2008; Lambertsen et al., 2012).
TNF-α is believed to play a detrimental role in ischemic injury,
since its neutralization with specific monoclonal antibodies
or binding proteins provides neuroprotection in experimental
stroke models (Barone et al., 1997; Nawashiro et al., 1997; Lavine
et al., 1998; Lambertsen et al., 2012). Nevertheless, studies from
transgenic animals demonstrate that the cytokine may also exert
beneficial effects through the activation of p55 TNF receptor
(TNF-RI) (Bruce et al., 1996; Gary et al., 1998; Taoufik et al.,
2007; Lambertsen et al., 2009). In rodents, expression of TNF-
RI is elevated in neurons and in non-neuronal cells few hours
after MCAo, whereas up-regulation of TNF-RII occurs from 24 h
after injury in resident microglia and infiltrating macrophages
(Botchkina et al., 1997; Dziewulska and Mossakowski, 2003;
Yin et al., 2004; Pradillo et al., 2005; Lambertsen et al., 2007).
Despite its predominant inflammatory role, TNF-RII has also
been implicated in neuroprotection (Marchetti et al., 2004), and
this further complicates the interpretation of the pleiotropic
effects of TNF in ischemic neuronal damage (Hallenbeck, 2002;
McCoy and Tansey, 2008).
Moreover, the TNF pathway has been involved in ischemic,
hypoxic, endotoxic and exercise-induced preconditioning
(Garcia-Bonilla et al., 2014a). In fact, LPS-preconditioned
TNF-α null mice are not protected from ischemic brain injury
(Rosenzweig et al., 2007) and administration of a neutralizing
TNF binding protein nullifies the beneficial effect of LPS
pre-treatment in spontaneously hypertensive rats subjected to
permanent MCAo (Tasaki et al., 1997). Paradoxically, TNF-α
has a dualistic effect in stroke, since it’s up-regulation has been
shown to underlie LPS-induced tolerance in mice subjected
to focal cerebral ischemia, whereas suppression of TNF-α
signaling during ischemia confers neuroprotection after LPS
preconditioning (Rosenzweig et al., 2007). Up-regulation of
TNF-α converting enzyme (TACE) and increased serum levels
of TNF-α have also been involved in preconditioning induced
by prolonged and intermittent normobaric hyperoxia in rats
subjected to MCAo (Bigdeli and Khoshbaten, 2008; Bigdeli
et al., 2008). In rats, the increased expression of TNF-α lasting
for 2–3 weeks of physical activity underlies amelioration of
downstream inflammatory events, reduced BBB disruption
and the consequent ischemic neuroprotection induced by
exercise preconditioning (Ding et al., 2005, 2006; Guo et al.,
2008b).
IL-1 is a proinflammatory cytokine that plays a pivotal role in
the neurodegenerative processes triggered by the ischemic insult
(Olsson et al., 2012; Dénes et al., 2013). Cerebral levels of both IL-
1α and IL-1β are elevated within hours of reperfusion after focal
ischemia (Hara et al., 1997; Amantea et al., 2007, 2010; Luheshi
et al., 2011). IL-1α is mainly induced in microglia, whereas IL-
1β can be released by all the elements of the neurovascular
unit, including neurons, astrocytes, microglia/macrophages and
endothelial cells, being its cellular source strongly dependent on
the spatio-temporal evolution of the damage (Amantea et al.,
2010; Luheshi et al., 2011; Giles et al., 2015). In astrocytes
and microglia, ischemia-induced production of IL-1β involves
activation of TLR4 (Simi et al., 2007) and p38 mitogen-activated
protein kinase (MAPK) (Walton et al., 1998; Irving et al., 2000).
Interestingly, under ischemic conditions, caspase-1-independent
pathways seem to contribute to IL-1β maturation. Accordingly,
it has been recently demonstrated that early elevation of IL-1β in
the ischemic cortex of rats subjected to transient MCAo is not
associated with caspase-1 activation, whereas production of the
mature cytokine is strongly dependent on gelatinases, i.e., MMP2
and MMP-9 activity (Amantea et al., 2007, 2014b).
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It is intriguing to observe that IL-1 is not directly toxic
to healthy neurons, whereas it may become harmful via the
modulation of other elements of the neurovascular unit, such
as astrocytes and the endothelium. IL-1 stimulates astrogliosis
(Herx and Yong, 2001) and prompts the release of cytokines,
chemokines (Andre et al., 2005) and the activation of MMP-9
in astrocytes (Thornton et al., 2008). Furthermore, this cytokine
induces endothelial expression of adhesion molecules, including
ICAM-1 and vascular cell adhesion molecule (VCAM)-1, that
together with the local stimulation of the release of chemokines,
promotes neutrophil adhesion and infiltration in the injured
hemisphere (Thornton et al., 2011; Allen et al., 2012).
Despite their established detrimental roles, both IL-1α and
IL-1β have been shown to underlie tolerance to global ischemia
induced by common carotid artery occlusion in gerbil (Ohtsuki
et al., 1996). Moreover, ischemic preconditioning produced
by bilateral common carotid artery occlusion protects mice
against subsequent MCAo injury by differentially regulating
cortical IL-1β and IL-1 receptor antagonist (IL-1ra) expression
in order to promote a shift toward an anti-inflammatory state
that contributes to neuroprotection (Shin et al., 2009). The
regulation of the expression and of the effects of IL-1 has also
been implicated in LPS preconditioning via the TLR4 signaling
pathway (Gong et al., 2014).
Other cytokines involved in the evolution of brain infarction
and contributing to aggravate neurological functions are IL-
17 and IL-23 (Shichita et al., 2009; Konoeda et al., 2010; Ma
et al., 2013; Swardfager et al., 2013). IL-17A secreted by γδ
T cells promotes neutrophil recruitment and its blockade with
specific antibodies exerts neuroprotection (Gelderblom et al.,
2012). Despite the presence of IL-17A-positive lymphocytes in
autoptic brain of stroke patients, IL-17 blood level does not seem
to be a good predictor of stroke outcome as compared to other
cytokines such as IL-6 (Zeng et al., 2013). In fact, plasma and
cerebrospinal fluid levels of IL-6 correlate with stroke severity
and poor clinical outcome in patients (Smith et al., 2004; Waje-
Andreassen et al., 2005; Whiteley et al., 2009) and reduced
blood concentrations of this cytokine have been correlated to the
improved outcome induced by treatment with IL-1ra (Emsley
et al., 2005). By contrast, in stroke animal models, IL-6 appears
to play a neuroprotective role (Matsuda et al., 1996; Loddick
et al., 1998; Herrmann et al., 2003), suggesting that its rapid and
persistent elevation in the ischemic brain (Suzuki et al., 1999;
Ali et al., 2000) may represent a compensatory mechanism to
counteract the damaging effects of the insult. In fact, by activating
its receptor and the downstream phosphorylation of STAT-3,
IL-6 may induce neuroprotection (Yamashita et al., 2005; Jung
et al., 2011). Moreover, IL-6 enhances the effectiveness of cell
transplantation therapy in ischemic stroke, by reprogramming
neural stem cells to tolerate oxidative stress and to induce
angiogenesis through STAT-3 activation (Perini et al., 2001).
Anti-Inflammatory Cytokines
While plasma concentrations of detrimental cytokines are
elevated, levels of IL-10, associated with better outcome, are
decreased in patients (Perini et al., 2001; Vila et al., 2003; Basic
Kes et al., 2008). Results from animal models demonstrate that
IL-10 represents a major downregulator of the detrimental effects
of proinflammatory mediators during stroke and modulates
neuronal vulnerability to excitotoxic ischemic damage (Spera
et al., 1998; Grilli et al., 2000; Frenkel et al., 2005).
Another cytokine playing beneficial effects in cerebral
ischemia is TGF-β (Gliem et al., 2012). Levels of this cytokine
are elevated in the blood of patients 1 day after ischemic
stroke (Yan et al., 2012) and in activated astrocytes and
microglia/macrophages of the ischemic brain for at least 1 week
in animal models (Lehrmann et al., 1998; Yamashita et al.,
1999; Doyle et al., 2010). In rats, administration of a TGF-
β antagonist aggravates brain damage caused by focal cerebral
ischemia (Ruocco et al., 1999); whereas, in mice, intranasal
delivery of this cytokine after stroke reduces infarct volume
and increases neurogenesis in the subventricular zone (Ma
et al., 2008). The beneficial effects of TGF-β involve both anti-
inflammatory effects, including inhibition of brain elevation of
MCP-1 and MIP-1α (Pang et al., 2001), but also induction of
glial scar formation (Logan et al., 1994) and anti-apoptotic effects
(Zhu et al., 2002).
In mice, preconditioning with low dose LPS is associated with
upregulation of anti-inflammatory cytokines, including TGF-β in
brain and IL-10 in blood (Vartanian et al., 2011).
Chemokines
In patients with acute ischemic stroke, serum levels of stromal
cell-derived factor (SDF)-1α have been correlated with favorable
long-term outcome (Kim et al., 2012) and this chemokine has
been suggested to be a predictor of future stroke (Schutt et al.,
2012). SDF-1α promotes bone marrow-derived cell targeting to
the ischemic brain and improves local cerebral blood flow (Cui
et al., 2007; Shyu et al., 2008), thus representing a promising
target to implement stem cell therapy in patients. In fact, in
the injured hemisphere, it activates CXCR4 on neural progenitor
cells guiding their specific migration to the site of damage (Robin
et al., 2006). Moreover, SDF-1α participates to the regulation of
post-ischemic inflammation and it is involved in neurovascular
repair (Wang et al., 2012). Despite these documented beneficial
effects, some detrimental roles have also been suggested to be
mediated by this chemokine, since pharmacological blockade of
CXCR4 is neuroprotective in stroke by reducing BBB damage and
inflammatory processes (Huang et al., 2013). Soluble fractalkine
(CX3CL1) released by neurons upon an ischemic insult controls
leukocyte trafficking and participates to the activation and
chemoattraction of microglia to the injured brain via the
activation of CX3CR1 receptors (Tarozzo et al., 2002; Dénes et al.,
2008; Zhu et al., 2009). The detrimental effects of this chemokine
are mediated by IL-1β and TNF-α in stroke mouse models
(Soriano et al., 2002; Dénes et al., 2008). By contrast, in ischemic
stroke patients, higher plasma concentrations of fractalkine are
associated with better outcome and with low levels of systemic
markers of inflammation (Donohue et al., 2012). In fact, by
inhibiting caspase-3 and by activating adenosine receptors,
exogenous administration of fractalkine is neuroprotective in
wild-type rodents undergone permanent ischemia (Cipriani
et al., 2011; Rosito et al., 2014). The apparent discrepancies
between this latter finding and those produced in transgenic
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animals may be explained by the alteredmicroglia responsiveness
to fractalkine in the absence of constitutive fractalkine-CX3CR1
signaling (Cipriani et al., 2011).
Among the chemokines implicated in cerebral ischemia,
MCP-1 (also known as CCL2) and MIP-1α have been shown
to play an important role in promoting tissue damage via
recruitment of inflammatory cells (Wang et al., 1995; Che
et al., 2001; Takami et al., 2001; Minami and Satoh, 2003). The
mRNA levels of both chemokines are elevated in the ischemic
brain of rodents and MCP-1 levels are also increased in the
cerebrospinal fluid of stroke patients (Losy and Zaremba, 2001).
Mice lacking MCP-1 or its receptor, CCR2, display reduced
infarct volume along with impaired leukocyte recruitment
and reduced expression of inflammatory mediators in the
injured brain (Hughes et al., 2002; Dimitrijevic et al., 2007;
Strecker et al., 2011; Schuette-Nuetgen et al., 2012). Conversely,
overexpression of MCP-1 prompts exacerbation of brain injury
and increased cerebral recruitment of inflammatory cells (Chen
et al., 2003). Moreover, MCP-1, as well as SDF-1α, promotes
migration of newly formed neuroblasts from neurogenic regions
to ischemic damaged areas (Robin et al., 2006; Yan et al.,
2007).
Up-regulation of MCP-1 has been shown to underlie hypoxic
preconditioning-induced stroke tolerance in mice (Stowe et al.,
2012; Wacker et al., 2012); whereas, activation of CCR2 is
involved in the neuroprotective effects exerted by both ischemic
preconditioning and post-conditioning in mice subjected to
global cerebral ischemia (Rehni and Singh, 2012).
Monocyte chemotactic protein-induced protein 1 (MCPIP1)
deficiency exacerbates ischemic brain damage by upregulation
of proinflammatory cytokines and this Zn finger-containing
immunoregulatory protein also participates in LPS- and
electroacupuncture-induced ischemic stroke tolerance (Liang
et al., 2001; Jin et al., 2013).
Enzymes: MMPs, COX, and NOS
MMPs play a crucial role in the evolution of the inflammatory
response to ischemic brain injury (Cunningham et al.,
2005). Stroke-induced damage to the BBB and hemorrhagic
transformation are both induced by the activation of the
gelatinases, MMP-2 and MMP-9, as demonstrated in animal
models (Romanic et al., 1998; Rosenberg et al., 1998; Asahi
et al., 2000) and in patients (Horstmann et al., 2003; Rosell et al.,
2006, 2008). RNA-expression levels of MMP-9 in circulating
monocytes have been correlated with the brain infarct lesion in
stroke patients (Ulrich et al., 2013); while, serum levels of this
enzyme have been associated with clinical diffusion mismatch
(Rodríguez-Yáñez et al., 2011).
Cerebral expression and activity of gelatinases increase very
early after an ischemic insult, with a specific cellular expression
pattern dependent on the spatio-temporal evolution of the
damage (Rosenberg et al., 1998; Planas et al., 2001; Yang et al.,
2007; Amantea et al., 2008). Pharmacological inhibition of
gelatinases, as well as gene deletion of MMP-9, reduces infarct
volume caused by focal cerebral ischemia in rodents (Romanic
et al., 1998; Asahi et al., 2000; Gasche et al., 2001; Amantea
et al., 2007, 2014b). The mechanisms by which gelatinases
contribute to ischemic brain damage include disruption of BBB
integrity, hemorrhagic transformation and white matter myelin
degradation (Cunningham et al., 2005). Moreover, MMPs and
their endogenous inhibitors (TIMPs) regulate neuronal cell
death through modulation of excitotoxicity (Jourquin et al.,
2003), DNA repairing enzymes (Hill et al., 2012), anoikis
(Gu et al., 2002), calpain activity (Copin et al., 2005) and
production of neurotoxic products (Gu et al., 2002; Zhang
et al., 2003), including pro-inflammatory cytokines (Amantea
et al., 2007, 2014b). Moreover, the degradation of tight junction
proteins claudin-5 and occludin by MMPs prompts hemorrhagic
transformation, suggesting that these enzymes may represent a
promising target for reducing the hemorrhagic complications
associated with thrombolytic therapy (Yang and Rosenberg, 2011;
Liu et al., 2012).
The up-regulation of the extracellular MMP inducer
(EMMPRIN) occurring in peri-ischemic regions 2–7 days
after focal ischemia in mice is coincident with the delayed
increase of MMP-9, suggesting its involvement in neurovascular
remodeling (Zhu et al., 2008). In fact, the late activation of
MMP-9 promotes vascular endothelial growth factor (VEGF)
signaling, contributing to neuronal survival and new vessels
formation (Zhao et al., 2006). Thus, MMPs play a dual role in
stroke injury, including early detrimental effects and beneficial
roles at later stages after the insult. Moreover, MMPs participate
to the protective response evoked by several preconditioning
stimuli. In fact, tolerance produced by ischemic preconditioning
or pre-ischemic exercise has been shown to be associated with
downregulation of MMP-9 and subsequent amelioration of brain
oedema and BBB disruption in rats undergone focal cerebral
ischemia (Zhang et al., 2006; Davis et al., 2007; Guo et al.,
2008a). Similarly, the neuroprotective action of TNF-α induced
by pre-ischemic physical exercise has been demonstrated to
occur via reduced MMP-9 activity and amelioration of BBB
dysfunction in rats subjected to transient MCAo, through
the involvement of extracellular signal-regulated kinase 1 and
2 (ERK1/2) phosphorylation (Guo et al., 2008b; Chaudhry
et al., 2010). Reduced activity of gelatinases was also associated
with the neuroprotective effects exerted by hyperbaric oxygen
preconditioning in hyperglycemic rats subjected to MCAo
(Soejima et al., 2013).
After an ischemic insult, the expression of COX-2 is elevated
in neurons, vascular cells and neutrophils, as demonstrated
both in stroke patients and in animal models (Nogawa et al.,
1997; Iadecola et al., 1999, 2001; Chakraborti et al., 2010).
This enzyme contributes to post-ischemic inflammation through
the production of toxic prostanoids and superoxide, and
its deficiency or pharmacological inhibition leads to reduce
BBB damage and to lower cerebral infiltration of leukocytes
in rodent models of ischemic stroke (Iadecola et al., 2001;
Candelario-Jalil et al., 2007). COX-2-derived prostaglandin E2
may also contribute to ischemic cell damage by disrupting Ca2+
homeostasis in neurons through activation of EP1 receptors
(Kawano et al., 2006). Interestingly, an association between
functional outcome and specific COX-2 variants has recently
been demonstrated in ischemic stroke patients (Maguire et al.,
2011).
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TABLE 2 | Acute ischemic stroke trials for the clinical validation of anti-inflammatory and immunomodulatory drugs.
Trial Drug Mechanism Phase Status
Safety Study of Interferon Beta 1a for
Acute Stroke
Recombinant human interferon beta-1a
(IFN-β1a) (Rebif®)
Inhibition of pro-inflammatory
cytokines production and prevention
of blood brain barrier disruption
I Completed
Intravenous immunoglobulin (IVIG) in acute
ischemic stroke: a pilot study
Immunoglobulin Scavenging active complement
fragments
I Withdrawn
Study of a neuroprotective drug to limit the





Acute stroke therapy by inhibition of
neutrophils (ASTIN)
Recombinant neutrophil inhibitory factor
(UK-279, 276)
Blockade of neutrophil adhesion to
endothelium
II Terminated
E-selectin nasal spray to prevent stroke
recurrence
E-selectin Induction of mucosal tolerance to
human E-selectin causing a shift of
immune response from T(H)1 to T(H)2
type
II Terminated
Study of interleukin-1 receptor antagonist
in acute stroke patients
IL-1 receptor antagonist IL-1β receptor blockade II Completed
Efficacy and safety of FTY720 for acute
stroke
The sphingosine-1-phosphate receptor
(S1PR) regulator Fingolimod (FTY720)
Reduced trafficking of T cells, B cells,
NK cells, and other S1PR-expressing
cells into the brain
II Recruiting
Controlled study of ONO-2506 in patients
with acute ischemic stroke
Arundic acid (ONO-2506) Astrocyte modulating agent II/III Completed
Hu23F2G Phase 3 stroke trial (HALT) Monoclonal antibody (humanized) against
the neutrophil CD11/CD18 cell adhesion
molecule, Hu23F2G (LeukArrest® )
Reduction of brain infiltration of
neutrophils
Pilot III Terminated
Enlimomab acute stroke trial (EAST) Murine anti-ICAM-1 Blockade of leukocyte attachment
and migration through cerebral
endothelium
III Completed
Neuroprotection with minocycline therapy




COX-2 has been implicated in hyperbaric oxygen
preconditioning, since pharmacological inhibition of this
enzyme abolishes the beneficial effects of the conditioning
stimulus in a rat model of transient global cerebral ischemia
(Cheng et al., 2011). Similarly, COX-2 induction participates
to ischemic tolerance induced by cortical spreading depression
(Horiguchi et al., 2006) or by a brief ischemic episode in rats
(Choi et al., 2006; Pradillo et al., 2009), likely via the stimulation
of the PGE2/PI3K/Akt pathway (Park et al., 2008). The elevated
expression of COX-2 induced by ischemic preconditioning
has been suggested to occur via a cascade involving epsilon
protein kinase C and ERK1/2 activation, as well as NFkB nuclear
translocation, as demonstrated in vitro (Kim et al., 2007, 2010).
While elevated expression of inducible NOS is associated
with ischemic (Cho et al., 2005), TLR4-mediated (Pradillo
et al., 2009) and anesthetic preconditioning (Kapinya et al.,
2002), induction of this enzyme has also been implicated in
the release of toxic amounts of NO by infiltrating neutrophils,
microglia/macrophages and endothelial cells (Nakashima et al.,
1995; Iadecola et al., 1996; Forster et al., 1999; Garcia-
Bonilla et al., 2014b). NO released by endothelial cells early
after the ischemic insult plays a beneficial role by inducing
vasodilatation; whereas, at later stages, overactivation of neuronal
NOS and, more importantly, de novo expression of inducible
NOS contribute to ischemic tissue damage (Iadecola et al.,
1996, 1997; Moro et al., 2004; Murphy and Gibson, 2007). In
fact, excessive production of NO by inducible NOS is cytotoxic
by promoting NFκB activation, by inhibiting ATP-producing
enzymes, by producing peroxynitrite and by stimulating other
pro-inflammatory enzymes such as COX-2 (Nogawa et al., 1998;
Greco et al., 2011). Moreover, NO contributes to ischemic cell
death via S-nitrosylation and, thereby, activation of glutamate
receptor (GluR)-6 signaling (Yu et al., 2008) and MMP-9 (Gu
et al., 2002).
NO plays a crucial role in cortical spreading depression-
induced tolerance to transient focal cerebral ischemia in
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rats (Horiguchi et al., 2005). Moreover, recent findings have
demonstrated the involvement of endothelial NOS in remote
ischemic preconditioning (Peng et al., 2012), while neuronal NOS
has been involved in the neuroprotection exerted by remote
post-conditioning (Pignataro et al., 2013).
Concluding Remarks
Although ischemic stroke is a major cause of mortality and
long-term disability worldwide (Go et al., 2014), current
therapeutic approaches for its acute treatment only rely
on blood flow restoration by thrombus lysis or removal
(Mangiafico and Consoli, 2014; Berkhemer et al., 2015; Hacke,
2015). The therapeutic window, intended as the temporal range
during which the endovascular treatment may reach the target
of a useful recanalization, is conventionally set at a threshold
of 6 h; therefore, only less that 10% of patients may actually
benefit from these procedures. Thus, the identification of novel
targets that allowwidening the time-window for pharmacological
intervention, as well as the possibility of limiting the development
of ischemic brain damage by promoting innate beneficial
responses, is a urgent challenge. To date, the clinical translation
of immunomodulatory drugs has been hampered by the fact that
most strategies tested in humans were purely based on anti-
inflammatory approaches (Table 2), disregarding the beneficial
roles of some elements of the immune reaction to stroke injury
(Amantea et al., 2014a). In this context, targeting immune
responses that evolve during hours or days after the ischemic
insult, by selectively promoting their beneficial components,
represents a promising avenue for the development of more
effective and safe stroke therapeutics.
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